KYTX
No price yet
Announcements
Nothing here yet
Daily updates
- Kyverna to Present Phase 2 KYSA-8 Data for KYV-101 in Stiff-Person Syndrome on October 21, 2026Oct 18, 2026
- Kyverna reported positive one-year registrational SPS data from KYSA-8 for single-dose miv-cel, showing sustained T25FW improvement, 92% of patients free from chronic SPS immunotherapies, and no high-grade CRS, ICANS, or IEC-HS.Sep 24, 2026
FDA designations
Nothing here yet
News
- Kyverna Therapeutics will present positive data in stiff person syndrome and progressive multiple sclerosis at MSToronto2026Oct 7, 2026
- Kyverna Therapeutics reports positive one-year data showing durable clinical responses and a favorable safety profile for miv-cel in stiff person syndrome and generalized myasthenia gravisSep 24, 2026
- Kyverna Therapeutics and ElevateBio sign commercial manufacturing and supply agreement for Miv-celJul 27, 2026
- Kyverna presented primary registrational trial results for Miv-cel in stiff person syndrome showing significant and durable clinical benefitApr 22, 2026
- Kyverna presented longer-term Phase 2 data for miv-cel in generalized myasthenia gravis showing deep and durable responses through 52 weeksApr 20, 2026